skin-diseases-and-microbiology-2016_scientifictracks

8 / 20

Volume 4, Issue 7(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal
Page 30
Notes:
Skin Diseases & Microbiology 2016
October 03-05, 2016
conferenceseries.com
October 03-05, 2016 Vancouver, Canada
International Conference on
Infectious Diseases, Diagnostic Microbiology &
Dermatologists Summit on Skin Infections
Towards skin point-of care devices for personalized skin treatment based on non-invasive biomarker
measurements directly from the skin surface
Pieter Spee
FibroTx LLC, Estonia
Diagnosis of chronic skin inflammation is largely performed by visual assessment, for instance by judging the shape, pattern,
position, thickness, redness and scaling of skin lesions on the body. These phenotypic characteristics are typically end-products
of the underlying biological processes responsible for disease. Despite the unquestionable value of visual assessment for treatment
decisions and patient monitoring, more detailed analyses methods are needed for answering the unmet medical need for offering
personalized medicine to patients, e.g., methods that can be used for selection as well as fine-tuning of treatment. Proteins that
play a crucial role in skin inflammation, such as cytokines and chemokines, form the molecular root of inflammation and thus
have tremendous value for catering personalized medicine in the form of biomarkers. Skin biomarker measurements are typically
performed on skin material obtained through invasive procedures and analyses are typically costly and elaborate. FibroTx TAP
and SELF are novel molecular diagnostic platform technologies for biomarker measurements directly from skin. These platform
technologies are currently being tested in clinical studies for the development of skin diagnostic tools that can objectively assess the
disease activity status of skin lesions. The aim of the studies is to develop practical point-of-care devices that can markedly improve
skin treatment, which is cost-efficient and does not require the need for extensive clinical laboratory expertise.
Biography
Pieter Spee has received his PhD in Immunology from the Netherlands Cancer Institute, University of Leiden. While at Novo Nordisk, he made significant contributions to
Lirilumab and Monalizumab, both currently in phase II clinical development by BMS and AstraZeneca in collaboration with Innate Pharma, respectively. As a Director and
Scientific Director, he was heading up preclinical translational research at Novo Nordisk. In 2012, he founded PS Pharmaconsult, offering expert advice on drug and medical
device development through a unique 360 degrees patient centric approach. Currently, he functions as a Chief Technology Officer at FibroTx LLC, developing two highly
innovative skin diagnostic devices, TAP and SELF, allowing personalized medicine in skin care and clinical dermatology.
Pieter Spee, J Infect Dis Ther 2016, 4:7(Suppl)